glp 1 neurodegenerative disease GLP-1 Receptor Agonists in Neurodegeneration: Neurovascular Unit in the Spotlight Glucagon-like peptide-1 medicines in neurological

Over a follow-up period of 26.2 months, empagliflozin significantly reduced the composite risk of HFH or cardiovascular death by 21% (13.8% versus 17.1%

doi: 10.2337/dc13-2618

Although rare, GLP-1 medications carry a small risk of pancreatitis, which requires prompt evaluation

The highly expressed calciuminsensitive synaptotagmin11 and synaptotagmin13 modulate insulin secretion

ALSO READ: Eli Lillys Mounjaro Becomes Indias Top-Selling Drug in 2025: Market View Outlook Indias push to manufacture affordable obesity drugs comes at a pivotal moment, coinciding with the global transition of semaglutide into the generic phase

The Promise of Tirzepatide: A Narrative Review of Metabolic Benefits